The study found that in a pool of 16,827 patients, nonarteritic anterior ischemic optic Neuropathy (NAION) increased more than four times for people taking semaglutide compared to those who took another drug
The ongoing TRIUMPH OUTCOMES trial will be key in determining the long-term cardio-renal effects of retatrutide in these populations
In many cases, employer-sponsored health plans exclude weight-loss medications altogether, even when obesity-related conditions significantly impact overall health outcomes
This is why we require individuals interested in our prescription weight loss medications, such as Compounded Semaglutide, Oral Semaglutide, Ozempig, Compounded Tirzepatide, Oral Tirzepatide, Mounjaro, Zepbound, and Wegovy, to complete our free assessment quiz